Table 3.
Co-resistance and cross-resistance in P. aeruginosa isolates.
| N | Number of resistant isolates (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CIP | LEV | MEM | IPM | CN | TIC | PIP | TIM | FEP | CAZ | ATM | ||
| CIP | 54 | - | 17 (31) | 4 (7) | 6 (11) | 44 (81)* | 33 (61) | 9 (17) | 10 (19) | 10 (19) | 9 (17) | 13 (24) |
| LEV | 17 | 17 (100) | - | 1 (6) | 2 (12) | 16 (94)* | 11 (65) | 3 (18) | 2 (12) | 2 (12) | 4 (24) | 2 (12) |
| MEM | 6 | 4 (67)* | 1 (17) | - | 5 (83)* | 5 (83)* | 5 (83)* | 5 (83)* | 3 (50) | 4 (67)* | 3 (50) | 5 (83)* |
| IPM | 8 | 6 (75)* | 2 (25) | 5 (63)* | - | 6 (75)* | 6 (75)* | 5 (63)* | 4 (50) | 4 (50) | 3 (38) | 5 (63)* |
| CN | 60 | 44 (73)* | 16 (27) | 5 (8) | 6 (10) | - | 34 (57)* | 9 (15) | 11 (18) | 10 (17) | 8 (13) | 14 (23) |
| TIC | 49 | 33 (67)* | 11 (22) | 5 (10) | 6 (12) | 6 (12) | - | 10 (20) | 15 (31) | 10 (20) | 9 (18) | 18 (37) |
| PIP | 13 | 9 (69)* | 3 (23) | 5 (38) | 5 (38) | 9 (69)* | 10 (77)* | - | 6 (46) | 7 (54)* | 4 (31) | 6 (46) |
| TIM | 16 | 10 (63)* | 2 (13) | 3 (19) | 4 (25) | 11 (69) | 15 (94)* | 6 (38) | - | 4 (25) | 4 (25) | 9 (56)* |
| FEP | 11 | 10 (91)* | 2 (19) | 4 (36) | 4 (36) | 10 (91)* | 10 (91)* | 7 (64)* | 4 (36) | - | 4 (36) | 7 (64)* |
| CAZ | 9 | 9 (100)* | 4 (44) | 3 (33) | 3 (33) | 8 (89)* | 9 (100)* | 4 (44) | 4 (44) | 4 (44) | - | 6 (67)* |
| ATM | 22 | 13 (59)* | 2 (9) | 5 (23) | 5 (23) | 14 (64)* | 18 (82)* | 6 (27) | 9 (41) | 7 (32) | 6 (27) | - |
Abbreviations: ATM, Aztreonam 30 µg; CAZ, Ceftazidime 10 µg; CIP, Ciprofloxacin 5 µg; CN, Gentamycin 10 µg; FEP, Cefepime 30 µg; IPM, Imipinem 10 µg; LEV, Levofloxacin 5 µg; MEM, Meropenem 10 µg; N, number of resistant isolates; PIP, Piperacillin 30 µg; TIC, Ticarcillin 75 µg; TIM, Ticarcillin/Clavulanic acid 85 µg; -, not applicable.
*
High cross resistance.